Does axillary dissection affect prognosis in T1 breast tumors?

Citation
Ce. Dimitrakakis et al., Does axillary dissection affect prognosis in T1 breast tumors?, EUR J GYN O, 20(5-6), 1999, pp. 403-407
Citations number
23
Categorie Soggetti
Reproductive Medicine
Journal title
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
ISSN journal
03922936 → ACNP
Volume
20
Issue
5-6
Year of publication
1999
Pages
403 - 407
Database
ISI
SICI code
0392-2936(1999)20:5-6<403:DADAPI>2.0.ZU;2-K
Abstract
Background: The treatment of patients with breast cancer has undergone many revisions over recent decades. The current trend is toward limited resecti ons and breast conservation. Some authors advocate the abandonment of axill ary lymph node dissection (ALND) for small tumors. While it is accepted tha t ALND has no therapeutic effect in breast cancer patients, its prognostic significance for small tumors is debated. Eligibility criteria for surgical treatment without axillary dissection are evolving. Methods: Considering that problem, we retrospectively reviewed the charts o f 100 patients with T1 invasive carcinoma of the breast treated at Hippokra tion Hospital of Athens between 1986 and 1987. Patients were divided into t wo groups: those that underwent ALND (n=76) and those that did not (n=24). The following data were recorded: age, tumor size, grade, hormone receptor status and postoperative treatment. The ten-year overall and disease-free s urvival were analysed. A multivariate analysis was used to identify prognos tic variables. Results: There was no statistically significant difference in the ten-year overall and disease-free survival between the two groups. The univariate an alysis showed that tumor size predicts both recurrence and survival. In the multivariate analysis tumor size was found to be an independent prognostic factor for overall survival. Conclusions: ALND did not influence the ten-year survival or the recurrence rate. Tumor size was the only statistically significant and independent pr ognostic factor for T1 breast cancer patients.